AzTrials
AzTrials

SchizophreniaPhase 3NCT03345342

A Study of Paliperidone Palmitate 6-Month Formulation

A Phase 3 study testing PP6M, PP3M 350 mg eq. and PP3M 525 mg eq. in people with Schizophrenia, run by Janssen Research & Development, LLC at 138 sites in 21 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants… Read more about this study

Who is it for?
Ages 18 to 70 years
Conditions the study is for
Schizophrenia
What is being tested?
PP6M, PP3M 350 mg eq. and PP3M 525 mg eq.
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
841 participants
Where
138 sitesin 21 countries
Study dates
20 Nov 2017to 8 May 2020
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 70 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Must meet the diagnostic criteria for schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5) for at least 6 months before screening
  • Must be receiving treatment with paliperidone palmitate (as either the paliperidone palmitate 1-month (PP1M) or paliperidone palmitate 3-month (PP3M) formulation), or injectable risperidone, or any oral antipsychotic
  • Must be able, in the opinion of the investigator, to discontinue any antipsychotic medication other than PP1M) or PP3M during the Screening Phase
  • Must have a full Positive and Negative Syndrome Scale (PANSS) score of less than (<) 70 points at screening
  • Must have a body mass index (BMI) between 17 and 40 kilogram (kg)/meter (m)^2 (inclusive) and must have a body weight of at least 47 kg at screening
  • Must be willing to receive gluteal injections of medication during the Double-blind Phase

Who cannot join

  • Must not be receiving any form of involuntary treatment, such as involuntary psychiatric hospitalization, parole-mandated treatment, or court-mandated treatment
  • Must not have attempted suicide within 12 months before screening and must not be at imminent risk of suicide or violent behavior, as clinically assessed by the investigator at the time of screening
  • Must not have a DSM-5 diagnosis of moderate or severe substance use disorder (except for nicotine and caffeine) within 6 months of screening; however, acute or intermittent substance use prior to screening is not exclusionary, depending upon the clinical judgment of the investigator
  • Must not have a history of neuroleptic malignant syndrome or tardive dyskinesia
  • Must not have a history of intolerability or severe reactions to moderate or higher doses of antipsychotic medications and must not have any other factors that would, in the judgment of the investigator, indicate that treatment with moderate or higher doses of paliperidone palmitate would be intolerable or unsafe

Trial locations and contacts

138 sites in 21 countries.

138 sites in 21 countries

United States25 sites
  • California Pharmaceutical Research Institute, Inc.

    Anaheim, California, 92804

  • Atlanta Center for Medical Research

    Atlanta, Georgia, 30331

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114

  • Uptown Research Institute

    Chicago, Illinois, 60640

  • Wexner Medical Center at the Ohio State University

    Columbus, Ohio, 43210

  • ATP Clinical Research

    Costa Mesa, California, 92626

  • Future Search Trials of Dallas

    Dallas, Texas, 75231

  • Midwest Clinical Research Center

    Dayton, Ohio, 45417

  • Collaborative NeuroScience Network

    Garden Grove, California, 92845

  • The Zucker Hillside Hospital

    Glen Oaks, New York, 11004

  • Cherry Street Services, Inc.

    Grand Rapids, Michigan, 49503

  • New Life Medical Research Center, Inc.

    Hialeah, Florida, 33012

  • Clinical Trials of America Inc

    Hickory, North Carolina, 28601

  • Alexian Behavioral Health Hospital

    Hoffman Estates, Illinois, 60169

  • Synergy East

    Lemon Grove, California, 91945

  • Clintex Research Group

    Miami, Florida, 33135

  • Florida Research Center Inc.

    Miami, Florida, 33174

  • Pacific Research Partners

    Oakland, California, 94607

  • University of Pennsylvania Medical Center

    Philadelphia, Pennsylvania, 19104

  • Woodland Research Northwest

    Rogers, Arkansas, 72758

  • Psychiatric and Behavioral Solutions

    Salt Lake City, Utah, 84105-2425

  • SF-Care, Inc

    San Rafael, California, 94901

  • St. Louis Clinical Trials

    St Louis, Missouri, 63141

  • Olympian Clinical Research

    Tampa, Florida, 33614

  • Ascension via Christi Research

    Wichita, Kansas, 67214

Other trials in United States

Russia12 sites
  • Clinical Psychiatric Hospital #3 Named After V.A. Gilyarovsky

    Moscow, 107076

  • Psychiatric Clinical hospital 1 named after N.A. Alekseev

    Moscow, 117152

  • Nizny Novgorod clinical psychiatric hospital 1

    Nizny Novgorod, 603155

  • Psychoneurological Dispensary of Frunzensky District

    Saint Petersburg, 190013

  • Psychoneurological dispensary 10

    Saint Petersburg, 190121

  • St-Petersburg Bekhterev Psychoneurological Research Institute

    Saint Petersburg, 192109

  • Psychoneurological dispensary 1

    Saint Petersburg, 199178

  • SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky

    Saratov, 410028

  • Saratov Regional Psychiatric hospital named after St. Sofia

    Saratov, 410060

  • Psychoneurological Dispensary #4

    St.Peterburg, 197110

  • Research Institute of Mental Health

    Tomsk, 634014

  • Sverdlovsk Regional Clinical Psychiatric Hospital

    Yekaterinburg

Other trials in Russia

Poland10 sites
  • Mlynowamed Specjalistyczny Psychiatryczny Gabinet Lekarski Joanna Lazarczyk

    Bialystok, 15-404

  • Wlokiennicza MED Specjalistyczna Praktyka Lekarska dr n.med. Tomasz Markowski

    Bialystok, 15-464

  • Zespol Opieki Zdrowotnej w Chelmnie

    Chełmno, 86-200

  • Centrum Badan Klinicznych PI House sp z o o

    Gdansk, 80 546

  • Szpital Specjalistyczny im H Klimontowicza Oddzial Psychiatryczny

    Gorlice, 38-300

  • Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS

    Leszno, 64-100

  • Centrum Medyczne Luxmed Sp z o o

    Lublin, 20 109

  • Poradnia Zdrowia Psychicznego 'Syntonia' w Pruszczu Gdanskim

    Pruszcz Gdański, 83-000

  • Mazowieckie Specjalistyczne Centrum Zdrowia im. Prof. Jana Mazurkiewicza w Pruszkowie

    Pruszków, 05-802

  • Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu

    Torun, 87 100

Other trials in Poland

Ukraine9 sites
  • MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association

    Hlevakha, 8630

  • Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'

    Kharkiv, 61068

  • CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council

    Kherson, 73488

  • Kyiv Territorial Medical Incorporation 'Psychiatry'

    Kyiv, 04080

  • Municipal Institution 'Lviv Regional Clinical Psycho-Neurological Dispensary'

    Lviv, 79017

  • CNCE of the Lviv Regional Council 'Lviv Regional Clinical Psychiatric Hospital'

    Lviv, 79021

  • CNCE Odesa regional psychiatric hospital #2 Odesa regional council

    Oleksandrivka, 67513

  • CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council'

    Smila, 20708

  • CNCE 'Vinnytsya RC Psychoneurological Hospital n.a. O.I. Yushchenko Vinnytsya RC'

    Vinnytsia, 21005

Other trials in Ukraine

India8 sites
  • Ratandeep Multispeciality Hospital

    Ahmedabad, 380008

  • Sri Ramachandra Medical Centre

    Chennai, 600116

  • Asha hospital

    Hyderabad, 500034

  • Ahana Hospitals

    Madurai, 625020

  • Vinaya Hospital and Research Center

    Mangalore, 575003

  • Kasturba Medical College Hospital

    Manipal, 576104

  • Jehangir Clinical Development Center Pvt Ltd

    Pune, 411001

  • Deva Institute of Health Care and Research Pvt Ltd

    Varanasi, 221005

Other trials in India

Brazil7 sites
  • Trial Tech Tecnologia em Pesquisas com Medicamentos

    Curitiba, 80240-280

  • Instituto Bairral de Psiquiatria

    Itapira, 13970-905

  • Hospital das Clinicas de Porto Alegre

    Porto Alegre, 90035-903

  • Ruschel Medicina e Pesquisa Clínica Ltda

    Rio de Janeiro, 22270 060

  • CPQuali Pesquisa Clinica LTDA ME

    São Paulo, 01228-900

  • SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo

    São Paulo, 04020-060

  • Hospital Das Clinicas Da Faculdade De Medicina Da USP

    São Paulo, 05403-903

Other trials in Brazil

Spain7 sites
  • Hosp Univ Vall D Hebron

    Barcelona, 08035

  • Inst. Internac. Neurociencias Aplicadas

    Barcelona, 8006

  • Hosp. Univ. de Basurto

    Bilbao, 48013

  • Centro Salud Mental La Corredoria

    Oviedo, 33011

  • Hosp. El Bierzo

    Ponferrada, 24404

  • Hosp. Clinico Univ. de Valencia

    Valencia, 46010

  • Hosp. Prov. de Zamora

    Zamora, 49021

Other trials in Spain

Argentina6 sites
  • Fundacion para el Estudio y Tratamiento de las Enfermedades Mentales

    Buenos Aires, C1133AAH

  • CEN

    Córdoba, X5004FJF

  • Sanatorio Prof. Leon S. Morra

    Córdoba, X5009BIN

  • Instituto de Neurociencias San Agustin

    La Plata, 1900

  • Clinica Privada de Salud Mental Santa Teresa de Ávila

    La Plata, B1904ADM

  • C I A P Centro de investigacion y Asistencia en Psiquiatria

    Rosario, 2000

Other trials in Argentina

Bulgaria6 sites
  • Mental Health Center Prof. Dr. Ivan Temkov

    Burgas, 8001

  • State Psychiatric Hospital Pazardzhik

    Pazardzhik, 4400

  • UMHAT 'Sveti Georgi'-Plovdiv

    Plovdiv, 4002

  • State Psychiatric HospitalDr.Georgi Kissiov

    Radnevo, 6260

  • Centre for Mental Health Prof.N.Shipkovenski EOOD

    Sofia, 1377

  • Medical Center Intermedica, OOD

    Sofia, 1680

Other trials in Bulgaria

Czechia6 sites
  • Psychiatricka ambulance, MUDr. Marta Holanova

    Brno, 61500

  • NeuropsychiatrieHK, s.r.o.

    Hradec Kralove-Vekose, 50341

  • A Shine S R O

    Pilsen, 31200

  • Pragtis S R O

    Prague, 12000

  • Institut Neuropsychiatricke pece

    Prague, 18600

  • Psychiatricka ambulance MUDr. Simona Papezova

    Prague, 19000

Other trials in Czechia

France5 sites
  • C.H.S. Charles Perrens

    Bordeaux, 33076

  • CHRU La Colombière

    Montpellier, 34090

  • CHU Caremeau

    Nîmes, 30029

  • Hopital Sainte Anne

    Paris, 75674

  • Hopital Sainte Musse

    Toulon, 83000

Other trials in France

Mexico5 sites
  • Gabipros SC

    Mexico City, 07810

  • Instituto Neuropsique

    Monterrey, 64610

  • Centro de Estudios Clinicos y Especialidades Medicas S C

    Monterrey, 64620

  • Infosame/Research

    Monterrey, 64710

  • Centro de Atencion e Investigacion Cardiovascular del Potosi S C

    San Luis Potosí City, 78200

Other trials in Mexico

Turkey (Türkiye)5 sites
  • Abdurrah Yurtarslan Training and Research Hospital

    Ankara, 6200

  • Ankara Numune Research and Training Hospital

    Ankara, 6800

  • Erenkoy Mental Health Hospital

    Istanbul, 34736

  • Selcuk University, Medical School, Department of Psychiatry

    Konya, 42130

  • Sakarya University Medical Faculty Psychiatry Department

    Sakarya, 54187

Other trials in Turkey (Türkiye)

Hungary4 sites
  • Józsefvarosi Szent Kozma Egészségügyi Központ

    Budapest, 1084

  • Petz Aladar Megyei Oktato Korhaz

    Győr, 9023

  • Bács-Kiskun Megyei Kórház a Szegedi Tudományegyetem Általános Orvostudományi Kar Oktató Kórháza

    Kalocsa, 6300

  • CRU Hungary Kft.

    Miskolc, 3529

Other trials in Hungary

Italy4 sites
  • Clinica Psichiatrica - Università di Cagliari

    Cagliari, 09127

  • Dipartimento di Salute Mentale

    Lecce, 73100

  • Seconda Universita degli Studi di Napoli - Azienda Ospedaliera Universitaria

    Naples, 80138

  • Universita degli Studi di Roma 'La Sapienza' - Azienda Ospedaliera Sant Andrea

    Roma, 00189

Other trials in Italy

Malaysia4 sites
  • Hospital Bahagia Ulu Kinta

    Ipoh, 31250

  • Hospital Kuala Lumpur

    Kuala Lumpur, 50586

  • University Malaya Medical Centre

    Kuala Lumpur, 59100

  • Sarawak General Hospital

    Kuching, 93586

Other trials in Malaysia

South Korea4 sites
  • Chonnam National University Hospital

    Gwangju, 61469

  • CHA Bundang Medical Center, CHA University

    Gyeonggi-do, 13496

  • Chonbuk National Univ Hospital

    Jeonju, 54907

  • Seoul National University Hospital

    Seoul, 03080

Other trials in South Korea

Taiwan4 sites
  • National Cheng Kung University Hospital

    Tainan, 70403

  • Mackay Memorial Hospital

    Taipei, 10449

  • Taipei Veterans General Hospital

    Taipei, 11217

  • Chang Gung Memorial Hospital

    Taoyuan, 333

Other trials in Taiwan

South Africa3 sites
  • Flexivest 14 Research

    Cape Town, 7550

  • Gert Bosch Pretoria South Africa

    Pretoria, 0042

  • Juan Schrönen - Western Cape South Africa

    Welgemoed, 7530

Other trials in South Africa

Australia2 sites
  • The Lyell McEwin Hospital

    Elizabeth Vale, 5112

  • Neuro Trials Victoria

    Noble Park, 3174

Other trials in Australia

Hong Kong2 sites
  • Kwai Chung Hospital

    Hong Kong

  • Queen Mary Hospital

    Hong Kong

Other trials in Hong Kong

About this study

Official title: A Double-blind, Randomized, Active-controlled, Parallel-group Study of Paliperidone Palmitate 6-Month Formulation

The purpose of this study is to demonstrate that injection cycles consisting of a single administration of paliperidone palmitate 6-month (PP6M) are not less effective than 2 sequentially administered injections of paliperidone palmitate 3-month PP3M) (350 or 525 mg eq.) for the prevention of relapse in participants with schizophrenia previously stabilized on corresponding doses of paliperidone palmitate 1-month (PP1M) (100 or 150 mg eq.) or PP3M (350 or 525 mg eq.).

Read the detailed description

The primary hypothesis of this study is that the efficacy of PP6M is non-inferior to PP3M for preventing relapse in participants with schizophrenia who were previously stabilized on corresponding doses of PP1M or PP3M. The study consists of mainly 3 phases: a screening phase (up to 28 days), a maintenance phase (of 1 or 3 months), and a double-blind phase (of 12 months [neither the researchers nor the participants know what treatment the participant is receiving]). Additional/conditional phases include a transition phase (before maintenance phase). Study evaluations include efficacy, pharmacokinetics, pharmacodynamics, and safety. The study duration will vary from approximately 13 months to 19 months.

Conditions
Schizophrenia
Being tested
PP6M, PP3M 350 mg eq., PP3M 525 mg eq., PP1M, Placebo
Medical subject headings
Schizophrenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PP6MDrug

    Also called R092670

    Participants will receive intramuscular injection of PP6M.

  • PP3M 350 mg eq.Drug

    Also called R092670

    Participants will receive intramuscular injection of PP3M 350 mg eq.

  • PP3M 525 mg eq.Drug

    Also called R092670

    Participants will receive intramuscular injection of PP3M 525 mg eq.

  • PP1MDrug

    Also called R092670

    Participants will receive intramuscular injection of PP1M 50 to 150 mg eq.

  • PlaceboOther

    Participants will receive matching placebo.

Study groups in NCT03345342
Study groupRoleWhat they receive
PP1M: Transition PhaseExperimentalParticipants who previously have not achieved stability with moderate to higher doses of Paliperidone palmitate 1-month (PP1M) or Paliperidone palmitate 3-month (PP3M) will enter into a transition period of up to 4 months. During transition period participants will receive 1 to 5 injections of PP1M 50 to 100 milligrams equivalent (mg eq.). The participants who achieved stability (stability is defined as at least 3 months of injections with the last 2 doses being the same strength) with PP1M 100 mg eq. will precede from transition phase to maintenance phase.
Receives: Drug: PP1M
PP1M/PP3M: Maintenance PhaseExperimentalAll the participants will receive only 1 dose of PP1M 100 or 150 mg eq. or PP3M 350 or 525 mg eq. The participants will precede from maintenance phase to double-blind phase.
Receives: Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.; Drug: PP1M
PP6M or Placebo: Double-Blind PhaseExperimentalParticipants will receive intramuscular injection of PP6M in left gluteal muscle on Day 1 and right gluteal muscle on Day 183 with alternating placebo in right gluteal muscle on Day 92 and left gluteal muscle on Day 274.
Receives: Drug: PP6M; Other: Placebo
PP3M: Double-Blind PhaseExperimentalParticipants will receive intramuscular injections of PP3M at dose of 350 mg eq. or 525 mg eq. in left gluteal muscle on Day 1 and 274 and right gluteal muscle on Day 92 and 183.
Receives: Drug: PP3M 350 mg eq.; Drug: PP3M 525 mg eq.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Time to Relapse During the Double-Blind (DB) Phase

    Time to relapse is time between participant randomization in DB Phase and first documentation of relapse event by end of Month 12 of DB phase. Relapse is defined as: a) Psychiatric hospitalization; b) Positive and Negative Syndrome Scale (PANSS) total score: Increase of 25 percentage (%), 10 point increase in PANSS for 2 analysis separated by 3-7 days if score was greater than (>) 40, less than or equal to (<=)40; c) Participants inflicted knowing self-injury/shown violent behavior leading to suicide, clinically significant injury to him/herself or other person/property; d) Participants had suicidal/homicidal ideation/violent behavior that was clinically significant as per investigator; e) PANSS items P1- delusions, P2- conceptual disorganization, P3-hallucinatory behavior, P6- suspiciousness/ persecution, P7-hostility, G8-uncooperativeness: score: greater than or equal to (>=)5, >=6 for 2 analysis separated by 3-7 days on any items if maximum score for PANSS: <=3 or 4, respectively.

    Measured: Up to 12 months of DB Phase

Secondary outcomes (19)
  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score

    The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and scores for 3 subscales: the 7-item positive-symptom (P) subscale, the 7-item negative-symptom (N) subscale, and the 16-item general-psychopathology symptom (G) subscale. Each item is rated on a scale from 1 (absent) to 7 (extreme). The PANSS total score ranges from 30 (absent disease)-210 (more severe neuropsychiatric symptoms of schizophrenia).

    Measured: Baseline (DB) to 12 Months of DB Phase

  2. Change From Baseline in the Clinical Global Impression - Severity (CGI-S) Score

    CGI-S is defined as clinician-rated scale that assesses the severity of mental illness on a scale of 0 to 7. Considering total clinical experience, a participant was assessed on severity of mental illness at the time of rating according to:1: normal, not at all ill; 2: borderline mentally ill; 3: mildly ill; 4: moderately ill; 5: markedly ill; 6: severely ill; 7: among the most extremely ill patients. A higher score implies a more severe condition.

    Measured: Baseline (DB) to 12 Months of DB Phase

  3. Change From Baseline in the Personal and Social Performance (PSP) Scale Total Score

    The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: 1) socially useful activities, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior. Each domain was assessed on a 6-point scale, from 1 (absent) to 6 (very severe) (1 = absent, 2 = mild, 3 = manifest, 4 = marked, 5 = severe, and 6 = very severe). PSP total score was calculated as sum of all the domain scores and ranges from 1 to 100. Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. Higher score indicates better performance.

    Measured: Baseline (DB) to 12 Months of DB Phase

  4. Percentage of Participants With Symptomatic Remission Based on PANSS Score During DB Phase

    Symptomatic remission was defined as achieving intensity level of mild or moderate on PANSS scale by all 8 items as the determinants for symptomatic remission: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, lack of spontaneity. The PANSS is a 30-item scale to assess the neuropsychiatric symptoms of schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self). The PANSS provides a total score and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each item scored on a scale of 1 (absent), 2 (minimal), 3 (mild), 4 (moderate), 5 (moderately severe), 6 (severe) and 7 (extreme). The total score ranges from 30 to 210 and higher score indicates greater severity.

    Measured: Up to 12 months of DB Phase

  5. Change From Baseline in the Satisfaction With Participants in Social Roles (SPSR) Score

    The SPSR Short Form 8a is a participant-reported outcome used to assess the satisfaction with participation in social roles. The participants were asked to rate 8 items on 5-point Likert scale, with scores ranging from 8 to 40, where higher scores represents higher satisfaction.

    Measured: Baseline (DB) to 12 Months of DB Phase

  6. Change From Baseline in the Treatment Satisfaction Questionnaire for Medication (TSQM-9) Total Score

    TSQM-9 consists of 9 questions to assess patients' satisfaction with medication using a range of responses from 1 (extremely dissatisfied) to (7 extremely satisfied). This patient reported outcome provides scores on three parts: effectiveness, convenience, and global satisfaction. The sum of the 9-questions were calculated and used for analysis. The total score ranges from 0 to 63, with higher scores indicating better treatment satisfaction.

    Measured: Baseline (DB) to 12 Months of DB Phase

  7. Change From Baseline in the Simpson-Angus Rating Scale (SAS) Total Score

    The SAS rates 10 items for general extrapyramidal symptoms (EPS) on a 5-point scale from 0 (normal) to 4 (extreme), including gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head rotation, Glabellar tap, tremor, and salivation. The SAS total score is the average score (total sum of item scores divided by the number of items) and ranges between 0 and 4. Negative change in score indicates improvement. Higher scores denote more severe condition of EPS.

    Measured: Baseline (DB) to 12 Months of DB Phase

  8. Number of Participants With Symptoms of Akathisia Assessed Using Barnes Akathisia Rating Scale (BARS) Score

    BARS is used to rate observable, restless movements of drug induced akathisia and subjective awareness of restlessness and any distress associated with the akathisia. BARS consists of the following 4 items: objective assessment of akathisia symptoms, subjective assessment of the participants's awareness of inner restlessness, distress restlessness, and global clinical assessment of akathisia. First three items are rated on a 4-point scale ranging from 0 (no abnormal movements or absence of inner restlessness or no distress) to 3 (severe akathisia or awareness of intense compulsion to move most of the time or severe distress). The last item, the global clinical assessment of akathisia, is rated on a 6-point scale, ranging from 0 (no evidence of akathisia) to 5 (severe akathisia).

    Measured: Up to 12 Months of DB Phase

  9. Change From Baseline in the Abnormal Involuntary Movement Scale (AIMS) Total Score

    AIMS is a 14-item scale. Items 1 to 8 are rated on a 5-point scale ranging from 0 (no dyskinetic movements) to 4 (severe dyskinetic movements). Item 9 assesses the participant's incapacitation due to abnormal movements, and item 10 assesses the participant's awareness of the abnormal movements and associated distress. Items 9 and 10 are rated on 5-point scales ranging from 0 (none or no awareness) to 4 (severe or aware, severe distress). Items 11 to 14 are yes/no questions regarding the global judgement and dental status of the participant. The total score is the sum of the scores for the 14 items and the possible total score ranges from 0 to 44. A higher total score is indicative of more severe dyskinetic movements.

    Measured: Baseline (DB) to 12 Months of DB Phase

  10. Number of Participants Based on Columbia Suicide Severity Rating Scale (C-SSRS) Total Score

    The C-SSRS is a questionnaire used for suicide risk assessment. Affirmative or negative responses are provided to items 1 to 5 for suicidal ideation (1. Wish to be dead, 2. Non-specific active suicidal thoughts, 3. Active suicidal ideation with any methods [not plan] without intent to act, 4. Active suicidal ideation with some intent to act, without specific plan, 5. Active suicidal ideation with specific plan and intent) and items 6 to 10 for suicide behavior (6. Preparatory acts or behavior, 7. Aborted attempt, 8. Interrupted attempt, 9. Actual attempt, 10. Completed suicide). Total score ranges from 1 to 10. Higher scores indicate more severe suicidal ideation.

    Measured: Baseline and endpoint (12 Months of DB Phase)

  11. Number of Participants With Treatment-emergent Abnormal Electrocardiogram (ECG) Values During DB Phase

    Number of participants with treatment-emergent abnormal ECG values were reported. It includes heart rate (abnormally low refers to less than or equal to [<=] 50 beats per minute (bpm) , abnormally high refers greater than or equal to [>=] 100 bpm), pulse rate (PR) interval (abnormally high refers to >= 210 milliseconds [msec]), QRS interval (abnormally Low refers to <= 50, abnormally high refers to >= 120 msec) and QT interval (abnormally low refers to <= 200, abnormally high >= 500 msec).

    Measured: Baseline (DB) to 12 Months of DB Phase

  12. Change From Baseline in the Body Mass Index (BMI) During DB Phase

    Change from baseline in BMI was reported.

    Measured: Baseline (DB) to 12 Months of DB Phase

  13. Change From Baseline in the Waist Circumference During DB Phase

    Change from baseline in waist circumference was reported.

    Measured: Baseline (DB) to 12 Months of DB Phase

  14. Change From Baseline in the Body Weight During DB Phase

    Change from baseline in body weight was reported.

    Measured: Baseline (DB) to 12 Months of DB Phase

  15. Change From Baseline in the Vital Signs (Pulse Rate) During DB Phase

    Change from baseline vital signs (pulse rate) were reported. This included supine pulse rate, standing pulse rate and supine-standing pulse rate.

    Measured: Baseline (DB) to 12 Months of DB Phase

  16. Change From Baseline in the Vital Signs (Systolic Blood Pressure [SBP] and Diastolic Blood Pressure [DBP]) During DB Phase

    Change from baseline in vital signs including SBP and DBP (supine/standing) were reported.

    Measured: Baseline (DB) to 12 Months of DB Phase

  17. Change From Baseline in Positive and Syndrome Scale (PANSS) Subscales Score During DB Phase

    The neuropsychiatric symptoms of schizophrenia were assessed using the 30-item PANSS scale, which provides a total score (sum of the scores for all 30 items) and Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology).

    Measured: Baseline (DB) to 12 Months of DB Phase

  18. Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Chemistry During DB Phase

    Number of participants with clinically significant abnormal laboratory values in chemistry included alanine aminotransferase (Unit per Litre [U/L]), albumin (Gram per Litre [g/L]), alkaline phosphatase (U/L), aspartate aminotransferase (U/L), bicarbonate (millimoles per litre [mmol/L]), bilirubin (micromoles per litre [umol/L]), calcium (mmol/L), chloride (mmol/L), cholesterol (mmol/L), creatinine (umol/L), gamma glutamyl transferase (GGT) (U/L), glucose (mmol/L), high-density lipoproteins (HDL) cholesterol (mmol/L), low density lipoproteins (LDL) cholesterol (mmol/L), lactate dehydrogenase (U/L), phosphate (mmol/L), potassium (mmol/L), protein (mmol/L), sodium (mmol/L), triglycerides (mmol/L), urate (umol/L), urea nitrogen (mmol/L) were reported. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.

    Measured: Up to 12 Months of DB Phase

  19. Number of Participants With Treatment-emergent Clinically Significant Abnormal Laboratory Values in Hematology During DB Phase

    Number of participants with clinically significant abnormal laboratory values in hematology included hemoglobin (Hb), hematocrit (Hct), red blood cell (RBC) count, white blood cell (WBC) count with differential, platelets, hemoglobin A1c. Here, ABL signifies abnormally low and ABH signifies abnormally high levels.

    Measured: Up to 12 Months of DB Phase

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Nov 2017
  2. Study start20 Nov 2017
  3. Primary completion8 May 2020
  4. Study completion8 May 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
841 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03345342
Sponsor's protocol ID
CR108390
Other IDs
R092670PSY3015, 2017-001941-28, 2017
Status last verified
Apr 2025
First submitted
14 Nov 2017
Last updated
29 Apr 2025
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Guirguis M, Knight RK, Sanga P, Han J, Galderisi S. Weight and metabolic changes in patients with schizophrenia treated with paliperidone palmitate 6-month formulation versus paliperidone palmitate 3-month formulation: a post-hoc analysis. Int J Neuropsychopharmacol. 2026 Sep 1;29(9):pyag042. doi: 10.1093/ijnp/pyag042.

    PubMed 42623271
  • Correll CU, Johnston KL, Turkoz I, Kutch M, Knight RK, Doring M, Sajatovic M. Comparing two transitioning strategies to paliperidone palmitate once-every-6-months. CNS Spectr. 2024 Dec;29(6):633-639. doi: 10.1017/S1092852924000476. Epub 2024 Nov 8.

    PubMed 39511777
  • Richarz U, Han J, Bai YM, Yu-Hai Chen E, Chung YC, Jhanwar VG, Kim SW, Sulaiman AH, Knight K, Gopal S. Efficacy and safety of paliperidone palmitate 6-monthly long-acting injectable in reduction of relapses in patients with schizophrenia: An Asian subgroup analysis of phase 3, randomized study. Medicine (Baltimore). 2023 Aug 25;102(34):e34623. doi: 10.1097/MD.0000000000034623.

    PubMed 37653768
  • Najarian D, Turkoz I, Knight RK, Galderisi S, Lamaison HF, Zalitacz P, Aravind S, Richarz U. Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia. Int J Neuropsychopharmacol. 2023 Aug 29;26(8):537-544. doi: 10.1093/ijnp/pyad028.

    PubMed 37480362
  • Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, Cohen K, Schotte A, Milz R, Venkatasubramanian R, T'Jollyn H, Walling DP, Galderisi S, Gopal S. A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251. doi: 10.1093/ijnp/pyab071.

    PubMed 34791283

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing PP6M, PP3M 350 mg eq. and PP3M 525 mg eq. in people with Schizophrenia, run by Janssen Research & Development, LLC at 138 sites in 21 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 138 sites in United States, Russia, Poland, Ukraine, India and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Dec 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Time to Relapse During the Double-Blind (DB) Phase (time frame: Up to 12 months of DB Phase). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03345342, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in